Meeting the testing needs for COVID-19
–
Multimodal Approach to SARS-CoV-2 Stratification
Solutions for both Laboratory & Individuals
In response to the COVID-19 global pandemic, Randox Laboratories have developed a range of diagnostic solutions to diagnose active SARS-CoV-2 infections, identify past infections and allow healthcare professional to monitor and support better management of COVID-19 adverse outcomes.
Randox aims to provide global testing solutions to mitigate current, resurgent societal reinfection and allow for the identification of emergent potentially more contagious variants.
Diagnosing active infections and managing resolved infections require different technologies to monitor and manage an individuals exposure to SARS-CoV-2 before and after symptom onset.
Active Infections
RT-PCR or Antigen tests detect the presence of SARS-CoV-2
Past Infections
Antibody tests to measure immune response to leading COVID-19 antigens
Solutions for Individuals
– Require a PCR or Antigen test for travel?
– Think you are infected with SARS-CoV-2?
– Curious if you have immunity to the virus or had a previous infection?
Randox Health have you covered!
PCR Testing
Antibody Testing
Antigen Testing
Solutions for Clinical, Pharma & Research Laboratories
Molecular
Immunological
Disease Management
Reagents | Extraction & qPCR
Designed to enable automated purification for accurate PCR detection of SARS-CoV-2
The Vivalytic | Solutions for the Point of Care
Rapid, fully automated all in one solution for molecular diagnostics
Rapid RT-PCR Detection of SARS-CoV-2 in 39 minutes
RT-PCR Detection of SARS-CoV-2 from up to 5 pooled samples simultaneously
SARS-CoV-2 detection & confirmatory testing
SARS-CoV-2 detection & differentiation of up to 10 viral respiratory infections
Biochip Technology | Medium / High Throughput Testing
Available on the Evidence Investigator & Randox Discovery
Extended Coronavirus Assay – Hi-Plex Molecular Assay for SARS-CoV-2 and 9 other viral targets
Surveillance | NGS Solutions for COVID-19
Identify existing & emerging SARS-CoV-2 variants
Deploying next generation sequencing aims to determine if a person has been infected with new emerging SARS-CoV-2 variants.
Available with Randox Clinical Laboratory Services (RCLS)
Antibody Testing | Determine Effective Immune Response to the most Immunogenic SARS-CoV-2 Antigens
Uniquely measure antibodies reactive to both Spike Receptor Binding Domain (RBD) and Nucleocapsid protein (NP)
SARS-CoV-2 IgG (RBD & NP) Array
Simultaneous detection of neutralising SARS-CoV-2 antibodies to identify immune responses, measure vaccine efficacy and deliver an accurate estimation of herd immunity
Clinical Profiling | Management & Monitoring of COVID-19 Associated Complications
Randox offers a comprehensive range of laboratory solutions including; diagnostics reagents, revolutionary Biochip technology and quality control designed to provide clinicians with valuable insights into disease severity ultimately helping to improve patient care.
Randox offer testing solutions for a comprehensive range of cytokines, cytokine receptors and growth factors designed to assist with COVID-19 risk stratification, monitoring of treatment efficacy and recovery. Utilising patented Biochip technology up to 12 cytokines and growth factors may be detected simultaneously from a single patient sample.
Cytokine storms are a common complication of SARS-CoV-2 (COVID-19) infection triggering viral sepsis, where viral replication and excessive, uncontrolled systemic inflammation may lead to pneumonitis, Acute Respiratory Distress Syndrome (ARDS), respiratory failure, shock, multiple organ failure, secondary bacterial pneumonia, and potentially death.
In addition to tests for the detection of SARS-CoV-2, the virus that causes COVID-19, laboratory diagnostics plays a pivotal role in patient management, risk stratification, monitoring of disease progression, associated complications and response to treatment.
Patients with comorbidities such as diabetes mellitus, cardiovascular disease (CVD) and chronic kidney disease (CKD) are particularly susceptible to COVID-19 infection and are at greater risk of developing severe illness. The Randox portfolio may also be used to diagnose and monitor such at risk patients with underlying health concerns.
